The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.

Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.

From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.

The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.